PGX

Drugs

Clopidogrel, Sertraline, Codeine, Doxepin, Clomipramine, Tramadol, Mercaptopurine

Gene	Pharmacovariants	Diplotype	Phenotype
CYP2C19	rs12769205/rs4244285	2/2	Poor Metabolizer
CYP2D6	rs28371732/rs16947-rs16947	1/2xN	Ultra-rapid Metabolizer
TPMT	rs1800462/rs1142345	2/3C	Poor Metabolizer

Drugs

Clopidogrel, Sertraline, Codeine,
Doxepin, Clomipramine, Tramadol, Metoprolol, Mercaptopurine

Gene	Pharmacovariants	Diplotype	Phenotype
CYP2C19	rs12769205/rs4244285	2/2	Poor Metabolizer
CYP2D6	rs28371732/rs16947-rs16947	1/2xN	Ultra-rapid Metabolizer
TPMT	rs1800462/rs1142345	2/3C	Poor Metabolizer

Novel Variants/Genes

Whole exome sequencing revealed rs140394156 variant in FMO2 gene.
J.S. is heterozygous for FMO2 missense non-synonymous variant c.497T>C p.(Phe166Ser) (details below), which is categorized as PATHOGENIC through multi-tools assessment.
The variant is predicted by SIFT, Polyphen2, CADD (as an independent tool), and Provean in addition to REVEL and MetaLR (in Ensembl variant table), VEP, VarSeq and VarAFT (comprehensive bioinformatic tools containing dbNSFP, ANNOVAR, FATHAMM, Mutation taster, Mutation assessor, etc.) to have a deleterious effect (damaging) upon protein function.

Gene FMO2	Transcript NM_001460.3	Nomenclature c.497T>C p.(Phe166Ser)	Zygosity Het	Consequence Missense variant
Inheritance ?	Classification Pathogenic	Assembly GRCh38	Pos 1:171199358	REF/ALT T/C
gnomAD AC/Ferq. 0.004	ACMG/ACGS PM2 & PP3 supportive	Phenotype -

None. This was a pre-emptive genotyping.

Considerations

For research use only
While ClinVAR listed this variant as "Likely Benign" for any clinical implications, but FMO2 protein (flavin containing dimethylaniline monoxygenase 2) is showing strong interaction with CYP family proteins as well as CYP2C9 and CYP2D6 within cellular pathway (string-db.org).